Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
about
Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy.Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.Hope and caution: report from the XI International Conference on AIDSThe significance of oral health in HIV diseaseEffects of drug abuse and mental disorders on use and type of antiretroviral therapy in HIV-infected personsSusceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analysesDevelopment and validation of a composite programmatic assessment tool for HIV therapyExpansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian settingUsing drug exposure for predicting drug resistance - A data-driven genotypic interpretation toolAntiretroviral therapy: Shifting sandsHIV-1 disease progression during highly active antiretroviral therapy: an application using population-level data in British Columbia: 1996-2011.Safety, pharmacokinetics, and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow-up in patients infected with human immunodeficiency virus.Long-term remission of HIV-associated thrombocytopenia parallels ongoing suppression of viral replicationApplications of flow cytometry to clinical microbiology.The cascade of HIV care in British Columbia, Canada, 1996-2011: a population-based retrospective cohort study.Current concepts in human immunodeficiency virus infection and AIDSA bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visitsLine probe assay for detection of human immunodeficiency virus type 1 mutations conferring resistance to nucleoside inhibitors of reverse transcriptase: comparison with sequence analysisUltrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasmaDelays in protease inhibitor use in clinical practiceAntiretroviral drug costs and prescription patterns in British Columbia, Canada: 1996-2011.Effect of early versus deferred antiretroviral therapy for HIV on survival.Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial dataThe drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.Absolute copy number and relative change in determinations of human immunodeficiency virus type 1 RNA in plasma: effect of an external standard on kit comparisons.A comparison of initial antiretroviral therapy in the Swiss HIV Cohort Study and the recommendations of the International AIDS Society-USA.Antiretroviral therapy for human immunodeficiency virus infection in 1997.Disparities in the burden of HIV/AIDS in CanadaEfavirenz use during pregnancy and for women of child-bearing potentialProcess monitoring of an HIV treatment as prevention program in British Columbia, Canada.Trends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010Does racial concordance between HIV-positive patients and their physicians affect the time to receipt of protease inhibitors?Physician specialization and antiretroviral therapy for HIV.HIV/AIDS patients' perspectives on adhering to regimens containing protease inhibitors.Zidovudine adherence in persons with AIDS. The relation of patient beliefs about medication to self-termination of therapyIs clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.Effect of race and/or ethnicity in use of antiretrovirals and prophylaxis for opportunistic infection: a review of the literature.Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies.AIDS incidence and AIDS-related mortality in British Columbia, Canada, between 1981 and 2013: a retrospective study
P2860
Q24514773-C4C7C80C-D685-4647-A3F1-BD1394E6B98EQ24534187-42C5B643-AD77-48B8-B1C0-5243F981A98DQ24536951-68D0957A-54BF-45BC-AA9A-E90A0837D6AAQ24679855-893B1650-55C2-4827-81D2-18CEBC62388AQ28353070-4A8B71F9-05C4-4DF7-BB8D-27ECBCDAB55BQ28379196-EEC1E6E7-40E5-4B42-8097-15299DA8F4A4Q28485260-4A11A2C3-DEE7-4664-96F7-DAAFB2A9E17EQ28539721-B7C791CC-2411-43E0-87CF-EEC21EA44F56Q30000270-CCB4AD1A-A006-47AA-8F1E-8877E66B2687Q30384683-7803FF33-8EBE-4D0F-9F05-3E035881CC60Q30679531-DA098871-9007-43F5-B585-78F10EEFB2E4Q33487821-07D2E747-F79B-47F6-BE9F-FA6E06F5BBBDQ33501309-EAC50F88-1C1A-40BB-8EF5-6374BFDFE2FBQ33555394-5CFE2AD3-21FF-4A7C-9ED3-70E469628FCBQ33598342-C7A6D8A5-D5D1-40BA-9EEF-262A65C19864Q33606809-48113830-5519-4159-BF40-463F5FBA2B1FQ33655217-49636DD2-BBF0-4C28-84D1-579CE4F0F1B4Q33675233-3F0C76C0-0BF1-42C2-A325-6D66EE760D70Q33678850-1813A76D-6C4A-492C-9F03-ADB10746843EQ33694010-529CEAB1-4D05-40A7-AAC6-25D706780130Q33713411-7E893051-73E9-4793-ADFE-1C4C9538C3D2Q33789114-4AD3EC3A-6FCF-4B14-9C5F-602CC391C6BEQ33891656-416F849D-C76E-484A-9453-0AEEBFE86EEDQ34065800-6195F5B7-0000-499E-B2A2-870277779BAEQ34073785-134F5AE6-66CF-449C-A71E-2D1811ADEEC3Q34113502-A8AEB6EC-FB38-4B61-8B79-16B877940689Q34185841-F7DF07BD-B5A1-4352-A7D2-B81E5F37EF78Q34499532-FA16DE31-EC61-4935-A0AA-CA02350FB6EAQ34632385-0D62C43B-5668-481C-8F0A-F99C80B50748Q34640731-CDDC47CD-96DD-4B8F-9D4F-E7EA9F1C7968Q34702301-EE038875-5716-4434-A4A1-7A0B363FB7F9Q34740792-180FB7A5-C773-4D6C-9A74-53E58A57D3A2Q34741264-EE0BD220-2019-4CCE-9408-6A9584AAAA74Q34752124-8CDDA180-6B57-4118-922F-823851B14657Q34752898-E670BC65-B645-4219-96FB-BF1784E3B1F3Q34926786-CD6C2A5D-FC81-4BC6-AA3E-70FABD190FEAQ34997253-D0EE4610-63EA-461F-823B-585E81A16E29Q35131540-2BA50F44-042A-40D8-B2FB-B978A4769C68Q35150769-2E083792-285B-471E-8286-CE2D6B32A20AQ35171945-410524FA-4929-42AF-B545-D54B5C2F80C3
P2860
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Antiretroviral therapy for HIV ...... nternational AIDS Society-USA.
@en
type
label
Antiretroviral therapy for HIV ...... nternational AIDS Society-USA.
@en
prefLabel
Antiretroviral therapy for HIV ...... nternational AIDS Society-USA.
@en
P2093
P1476
Antiretroviral therapy for HIV ...... nternational AIDS Society-USA.
@en
P2093
C C Carpenter
D A Katzenstein
D D Richman
D M Jacobsen
J S Montaner
M A Fischl
M A Thompson
M S Hirsch
P A Volberding
P304
P356
10.1001/JAMA.1996.03540020068031
P407
P577
1996-07-01T00:00:00Z